Impact of the French Infectious Diseases Society's (SPILF) proposals for shorter antibiotic therapies

G Macheda1, A Luc2, G Béraud3

  • 1Infectious diseases department, université de Lorraine, CHRU de Nancy, 54000 Nancy, France.

Abstract

Insights

French infection specialists increasingly advised shorter antibiotic therapy durations between 2016 and 2018. This shift aligns with new guidelines, indicating a positive impact on antibiotic stewardship practices.

Area of Science:

  • Infectious Diseases
  • Antimicrobial Stewardship
  • Clinical Practice Guidelines

Background:

  • Antibiotic therapy duration is a key component of antimicrobial stewardship.
  • Variability in recommended durations can impact treatment outcomes and resistance.
  • Understanding specialist practices is crucial for optimizing antibiotic use.

Purpose of the Study:

  • To compare French infection specialists' antibiotic therapy duration recommendations in 2016 versus 2018.
  • To assess the influence of updated guidelines on specialist practices.

Main Methods:

  • Two identical surveys administered to hospital-based infection specialists in 2016 and 2018.
  • Surveys included 15 clinical vignettes assessing usual and shortest recommended antibiotic therapy durations.
  • Participants were medical physicians and pharmacists advising on antibiotic prescriptions.

Main Results:

  • A significant increase in advising shorter antibiotic durations was observed in 2018 (71%) compared to 2016 (46%).
  • Guideline adherence for fixed durations rose from 21% in 2016 to 77% in 2018.
  • Awareness of the 2017 SPILF guidelines was high among specialists in 2018 (89%).

Conclusions:

  • The introduction of guidelines advocating shorter antibiotic therapy durations positively influenced specialist practices.
  • These findings suggest successful implementation of evidence-based recommendations in clinical settings.
  • Optimized antibiotic prescribing through guideline adoption can enhance antimicrobial stewardship.

Related Concept Videos

Healthcare Associated Infections II: Preventive Measures01:22

Healthcare Associated Infections II: Preventive Measures

Essential infection prevention measures are based on the knowledge of the infection chain, the modes of transmission in healthcare settings, and the use of the best practices in all healthcare settings. Compulsory public reporting of healthcare-associated infection rates is needed to allow individuals and the community to make informed choices regarding selecting a healthcare facility.
The best practices for preventing healthcare-associated infections include hand hygiene, patient risk...
Pharmacokinetic–Pharmacodynamic Relationship: Influence of Elimination Half-Life on Effect Duration01:23

Pharmacokinetic–Pharmacodynamic Relationship: Influence of Elimination Half-Life on Effect Duration

Drug elimination from the body primarily occurs through metabolic and excretion pathways. Hepatic metabolism transforms lipophilic drugs into hydrophilic forms for excretion, typically via enzymatic processes classified as phase I (modification) and phase II (conjugation). Renal excretion eliminates drugs and metabolites through filtration and secretion in the kidneys. Impairment in liver or kidney function can hinder these processes, delaying drug clearance and extending the drug’s half-life.
Microbiota Modulation by Antibiotics01:21

Microbiota Modulation by Antibiotics

Antibiotics have revolutionized modern medicine by saving countless lives from bacterial infections. However, their widespread use has inadvertently harmed the delicate balance of the human gut microbiota. The gut microbiota, a complex community of bacteria, archaea, viruses, and fungi, plays a vital role in regulating metabolism, immune responses, and maintaining intestinal health. Antibiotics, especially broad-spectrum types, disrupt this ecosystem by eradicating both harmful and beneficial...
Mechanism of Antibiotic Resistance in MRSA01:25

Mechanism of Antibiotic Resistance in MRSA

Antibiotic resistance in bacteria arises when microorganisms evolve the ability to withstand drugs designed to kill them or inhibit their growth, rendering once-effective treatments useless. This phenomenon, driven by genetic change and selection under antibiotic exposure, poses a profound threat to modern medicine. Mechanisms include drug-inactivating enzymes (e.g., β-lactamases), efflux pumps that eject antibiotics, mutations altering antibiotic targets, decreased drug uptake, and acquisition...
Inhibitors of Bacterial DNA Synthesis01:28

Inhibitors of Bacterial DNA Synthesis

Bacterial pathogens depend on precise and efficient DNA replication to sustain infection. Two type II topoisomerases—DNA gyrase and topoisomerase IV—are critical to this process, as they resolve DNA supercoiling and unlink chromosomes during replication. Fluoroquinolones, synthetic derivatives of quinolones, exploit this mechanism by stabilizing the transient DNA–enzyme cleavage complex, preventing strand religation, and causing lethal double-strand breaks. These antibiotics are selectively...
Clinical Significance of Antibiotic Resistance01:25

Clinical Significance of Antibiotic Resistance

Methicillin-resistant Staphylococcus aureus (MRSA) presents a critical public health threat, arising from its capacity to resist β-lactam antibiotics due to acquisition of the mecA gene within the staphylococcal cassette chromosome mec (SCCmec). This gene encodes penicillin-binding protein 2a (PBP2a), which impairs binding efficacy of methicillin and other β-lactams. MRSA has evolved into distinct clonal lineages impacting humans and animals alike, reinforcing its significance within the One...